Compare INOD & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INOD | VRCA |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | United States |
| Employees | 3000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 137.3M |
| IPO Year | 1996 | 2018 |
| Metric | INOD | VRCA |
|---|---|---|
| Price | $95.93 | $6.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $100.00 | $17.00 |
| AVG Volume (30 Days) | ★ 2.5M | 91.5K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.37 | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $86,775,000.00 | $35,577,000.00 |
| Revenue This Year | $38.42 | N/A |
| Revenue Next Year | $27.03 | $94.44 |
| P/E Ratio | $215.48 | ★ N/A |
| Revenue Growth | 9.84 | ★ 370.22 |
| 52 Week Low | $33.79 | $0.49 |
| 52 Week High | $114.77 | $9.82 |
| Indicator | INOD | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 76.46 | 45.40 |
| Support Level | $40.21 | $6.15 |
| Resistance Level | N/A | $6.40 |
| Average True Range (ATR) | 9.06 | 0.68 |
| MACD | 5.22 | -0.09 |
| Stochastic Oscillator | 74.92 | 7.45 |
Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.